- Trial Phase
- Phase 2 (completed) / Phase 2b/3 (planned for H1 2026)
- Time to Market
- At least 3-4 years assuming successful Phase 2b/3 and subsequent Phase 3 or filing, given no therapy has ever been FDA-approved for NCP
- Why 5/10
- The next hard binary catalyst is topline data from the planned 120-patient Phase 2b/3 trial of urcosimod for neuropathic corneal pain. The trial was expected to initiate in H1 2026 but has no confirmed start or topline date yet. With no imminent PDUFA or precisely dated readout, the impact score is capped at 5 — urcosimod is the company's sole pipeline asset, so a positive readout would be transformative, but the catalyst is not locked to a near-term calendar date.
Watch for announcement of first patient dosed in the Phase 2b/3 trial — that's the next concrete derisking step. The stock trades at a steep discount (~$1.61) to the analyst mean price target of $9, reflecting execution and financing risk. Any delay in trial initiation or need for dilutive financing would pressure shares; positive topline data could drive a multi-bagger. The near-term binary (trial start) is less impactful than the topline readout (expected late 2026 into 2027).
Price Chart
Executive Summary
Urcosimod (formerly OK-101) is OKYO Pharma's sole pipeline asset — an investigational eye-drop for neuropathic corneal pain (NCP), a chronic condition with no FDA-approved therapies. A small but positive Phase 2a trial (18 patients) showed 75% of patients on 0.05% urcosimod achieved >80% pain reduction at 12 weeks. The FDA has granted Fast Track designation and endorsed a 120-patient Phase 2b/3 design. OKYO is a micro-cap (~$70-86M market cap) with strong analyst support (8 Buy-equivalent ratings, mean price target $9 vs ~$1.61 current). However, the company has limited cash runway and will almost certainly need dilutive financing to complete the pivotal program, making this a high-risk/high-reward single-asset story.
How It Works
Urcosimod is an eye-drop that activates a specific receptor (ChemR23) found on immune cells and nerve cells in the eye. By docking onto this receptor, it dials down inflammation and reduces pain signals — essentially calming both the inflammatory response and the abnormal nerve firing that causes chronic eye pain. A lipid anchor in the molecule helps it stick to the eye surface longer so it doesn't wash away quickly.
Trial Status
An 18-patient Phase 2a trial for neuropathic corneal pain (NCP) completed with positive topline results announced July 2025. A larger 240-patient Phase 2 trial for dry eye disease also completed earlier with positive results. The FDA granted Fast Track designation (May 2025) and a successful Type C meeting (Jan 2026) endorsed a 120-patient, randomized, multiple-dose Phase 2b/3 trial design. The company plans to initiate that study in H1 2026. A single-patient compassionate-use IND was also authorized by the FDA in January 2026.
The Two-Sided Case
Upcoming Catalysts
- Initiation of the 120-patient Phase 2b/3 multiple-dose trial (expected H1 2026) — first patient dosed announcement.
- Topline data from the Phase 2b/3 trial (estimated late 2026 into 2027).
- Presentation of Phase 2 NCP data at ASCRS 2026 annual meeting.
- Potential additional non-dilutive grant funding or partnership announcements.
- Possible advancement of dry eye disease program as a second indication.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
OKYO Pharma Ltd 6-K OKYO ·Originating report